MRNA חוב כולל להון Moderna Therapeutics

Leadership in mRNA technologies provides Moderna, Inc. (MRNA) with pricing power, which is evident in the company's financial leverage history. The value of 0.18 reflects the latest debt load metric. Business protection is based on strict patents and FDA oversight, however, the decline in COVID-related revenues necessitates the urgent launch of new respiratory drugs to stabilize profits.

Investors utilize leverage multiples to verify the financial stability of an issuer. This metric compares total liabilities to equity, and the current debt-to-equity ratio clearly demonstrates the business's degree of dependence on creditors. A rising trend signals increased bankruptcy risks. This is critical for Moderna, Inc. (MRNA), as falling vaccine demand and failed trials could accelerate the cash burn. A low indicator value confirms the company's ability to weather technological crises.